The EU CE mark for the companies’ AI-powered AiMIFY software for enhancing contrast MRI scans follows its FDA clearance in ...

Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration.

NEW ORLEANS — For contrast-enhanced imaging in multiple sclerosis (MS), all gadolinium-based agents accumulate in body tissue but to greatly varying degrees. While the long-term effect of ...

Adverse reactions from gadolinium-based contrast agents used during MRI rarely occur, study suggests Date: January 21, 2010 Source: American College of Radiology / American Roentgen Ray Society ...

Now, a revolutionary gadolinium-free contrast agent, RVP‑001, designed to provide safer contrast-enhanced MRIs for patients and to directly replace current MRI contrast agents, is being tested ...

Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at ...

“The current evidence does not support withholding group II gadolinium-based contrast agents from patients on the basis of NSF risk alone,” Dr. Shankar concludes. “Therefore, group II agents ...

A new, specially coated iron oxide nanoparticle developed by a team at MIT and elsewhere could provide an alternative to conventional gadolinium-based contrast agents used for magnetic resonance ...

For all GBCAs, "the necessity of MRI scan using gadolinium-based contrast agents should be determined carefully" as stated in the Japanese new package insert. Magnetic resonance imaging (MRI ...

Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis in patients with kidney problems, according to a new study. NSF is a rare ...